Literature DB >> 10417624

Haplotype analysis of families with erythropoietic protoporphyria and novel mutations of the ferrochelatase gene.

X Wang1, L Yang, L Kurtz, A Lichtin, V A DeLeo, J Bloomer, M B Poh-Fitzpatrick.   

Abstract

Ferrochelatase, the enzyme that catalyzes the terminal step in the heme biosynthetic pathway, is the site of the defect in the human inherited disease erythropoietic protoporphyria. Molecular genetic studies have shown that the majority of erythropoietic protoporphyria cases are transmitted in dominant fashion and that mutations underlying erythropoietic protoporphyria are heterogeneous. We performed haplotype analysis of American families that shared recurrent ferrochelatase gene mutations yet had forbearers from several European countries. This was to gain insight into whether these mutations represent mutational hotspots at the ferrochelatase gene, or propagation of ancestral alleles bearing the mutations. Two recurrent mutations were found to occur on distinctive chromosome 18 haplotypes, consistent with being hotspot mutations. On the other hand, we found three sets of two unrelated families that shared the same haplotypes bearing these mutations, which could reflect geographic dispersion of ancestral mutant alleles. In addition, we report novel mutations associated with erythropoietic protoporphyria: g(+ 1)-->t transversion of the exon 4 donor site, g(+ 1)-->a transition of the exon 6 donor site, and t(+ 2)-->a substitution at the exon 9 donor site; these mutations are predicted to cause splicing defects of the associated exons. We also identified a g(+ 5)-->a transition of the exon 1 donor site in four unrelated families with erythropoietic protoporphyria, and a G(- 1)-->A substitution at the exon 9 donor site in an additional family. The probability that these sequence changes are normal polymorphisms was virtually excluded (p < 0.0001) by their absence in 120 ferrochelatase alleles from 30 normal subjects and 30 individuals with manifested erythropoietic protoporphyria with or without a known mutation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417624     DOI: 10.1046/j.1523-1747.1999.00637.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2.

Authors:  Sharon S Cooperman; Esther G Meyron-Holtz; Hayden Olivierre-Wilson; Manik C Ghosh; Joseph P McConnell; Tracey A Rouault
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

Review 2.  Theodore Woodward Award. Pathogenesis of biochemical abnormalities in protoporphyria.

Authors:  J R Bloomer; M B Poh-Fitzpatrick
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

3.  Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria.

Authors:  Pyoung-Jae Park; Shin Hwang; Young-Il Choi; Young-Dong Yu; Gil-Chun Park; Sung-Won Jung; Sam-Youl Yoon; Gi-Won Song; Tae-Yong Ha; Sung-Gyu Lee
Journal:  Clin Mol Hepatol       Date:  2012-12-21

4.  Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.

Authors:  Manisha Balwani; Dana Doheny; David F Bishop; Irina Nazarenko; Makiko Yasuda; Harry A Dailey; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Lawrence Liu; Robert J Desnick
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

5.  Ultraviolet A phototest positivity is associated with higher free erythrocyte protoporphyrin IX concentration and lower transferrin saturation values in erythropoietic protoporphyria.

Authors:  Giovanni Genovese; Carlo Alberto Maronese; Chiara Moltrasio; Roberta Piccinno; Dario Antonio Marletta; Giacomo De Luca; Giovanna Graziadei; Francesca Granata; Elena Di Pierro; Maria Domenica Cappellini; Angelo Valerio Marzano
Journal:  Photodermatol Photoimmunol Photomed       Date:  2021-08-30       Impact factor: 3.254

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.